Real-world risk of diabetes with antipsychotic use in older New Zealanders: a case-crossover study

[1] Stahl SM(1999)Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials The Journal of clinical psychiatry 60 31-41

[2] Jakovljevic M(2009)New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence Psychiatr Danub 21 446-452

[3] Lambert M(2011)Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models J Clin Psychopharmacol 31 226-230

[4] Schimmelmann BG(2003)A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States J Clin Epidemiol 56 164-170

[5] Schacht A(2002)The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis The Journal of clinical psychiatry 63 1135-1139

[6] Suarez D(2004)Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States J Am Med Dir Assoc 5 38-46

[7] Haro JM(2003)Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine Pharmacotherapy 23 1037-1043

[8] Novick D(2011)Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC psychiatry 11 197-799

[9] Wagner T(2009)The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study Pharmacoepidemiol Drug Saf 18 791-612

[10] Wehmeier PM(2004)An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia Control Clin Trials 25 598-392

[1] Stahl SM(1999)Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials The Journal of clinical psychiatry 60 31-41

[2] Jakovljevic M(2009)New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence Psychiatr Danub 21 446-452

[3] Lambert M(2011)Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models J Clin Psychopharmacol 31 226-230

[4] Schimmelmann BG(2003)A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States J Clin Epidemiol 56 164-170

[5] Schacht A(2002)The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis The Journal of clinical psychiatry 63 1135-1139

[6] Suarez D(2004)Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States J Am Med Dir Assoc 5 38-46

[7] Haro JM(2003)Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine Pharmacotherapy 23 1037-1043

[8] Novick D(2011)Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC psychiatry 11 197-799

[9] Wagner T(2009)The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study Pharmacoepidemiol Drug Saf 18 791-612

[10] Wehmeier PM(2004)An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia Control Clin Trials 25 598-392